Relapsing/refractory HL after autotransplantation: which treatment?
Keywords:
Hodgkin Lymphoma, Relapsing/refractory HL, autologous transplantationAbstract
For advanced-stage Hodgkin lymphoma (HL), front-line chemotherapy, alone or in combination with radiotherapy, leads to 5-year progression-free survival (PFS) rates and freedom-from-treatment failure (FFTF) rates of 70-85%, regardless of the chemotherapy regimen applied. Patients with HL experiencing disease progression during or within 3 months of front-line therapy (primary refractory) and patients whose disease relapses after a complete response have a second chance of treatment. The standard of care for relapsed or refractory HL is second-line chemotherapy followed by autologous stem cell transplantation (ASCT), which can induce long-term remission in approximately 40-50% of patients. However, HL recurrence occurs in about 50% of patients after ASCT, usually within the first year, and represents a significant therapeutic challenge. Allogeneic transplantation from HLA-matched donors represents the standard of care for patients with HL relapsing after- or refractory to ASCT.
References
1. Bröckelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 2018;131(15):1666- 1678.
2. Adams HJ, Kwee TC. Controversies on the prognostic value of in- terim FDG-PET in advanced-stage Hodgkin lymphoma. Eur J Hae- matol 2016; 97(6):491-498.
3. Rigacci L, Puccini B, Zinzani PL et al. Clinical Characteristics of patients with negative interim-PET and positive final PET: data from the prospective PET-oriented HD0801 study by Fondazione Italiana Linfomi (FIL). Hematological Oncology 2017; 35(S2).
4. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Posi- tive Interim Positron Emission Tomography/Computed Tomog- raphy Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Gallamini A, Tarella C, Viviani S, et al. J Clin Oncol 2018; 36(5):454-462.
5. Dann EJ, Bairey O, Bar-Shalom R et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on in- terim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol 2017; 178(5):709-718.
6. Borchmann P, Haverkamp H, Lohri A et al. Progression-free sur- vival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol 2017;18(4):454-463.
7. Zinzani PL, Broccoli A, Gioia DM et al. Interim Positron Emis- sion Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J Clin Oncol 2016;34(12):1376-1385.
8. Rigacci L, Puccini B, Zinzani PL et al. The prognostic value of positron emission tomography performed after two courses (IN- TERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 2015;90(6):499-503.
9. Ciammella P, Filippi AR, Simontacchi G et a. Post-ABVD/pre-ra- diotherapy (18)F-FDG-PET provides additional prognostic infor- mation for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Br J Radiol 2016;89(1061):20150983.
10. Simontacchi G, Filippi AR, Ciammella P et al. Interim PET Af- ter Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Out- comes Following the Continuation of Chemotherapy Plus Radio- therapy. Int J Radiat Oncol Biol Phys 2015;92(5):1077-1083.
11. Keresztes K, Lengyel Z, Devenyi K, Vadasz G, Miltenyi Z, Illes
A. Mediastinal bulky tumour in Hodgkin’s disease and prognostic value of positron emission tomography in the evaluation of post- treatment residual masses. Acta Haematol 2004;112(4):194-199.
12. Sickinger MT, von Tresckow B, Kobe C, Borchmann P, Engert A, Skoetz N. PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis. Crit Rev Oncol Hematol 2016;101:86-92.
13. Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N. Positron emission tomography-adapted therapy for first- line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst Rev 2015; 9;1: CD010533.
14. Adams HJA, de Klerk JMH, Regelink JC, Heggelman BGF, Dubois SV, Kwee TC. Radiation-Induced Giant Cell Granuloma Mimick- ing Relapsed Hodgkin Lymphoma at FDG-PET/CT. Nucl Med Mol Imaging 2017;51(4):371-373.
15. Radhakrishnan RK, Mittal BR, Basher RK, Prakash G, Malhotra P, Kalra N, Das A. Post-therapy lesions in patients with non- Hodgkin’s lymphoma characterized by 18F-FDG PET/CT-guided biopsy using automated robotic biopsy arm. Nucl Med Commun 2018;39(1):74-82.
16. Adams HJ, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol 2016;95(5):695-706.
17. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al. The impact of pre- and post-transplantation positron emis- sion tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplanta- tion. Cancer 2007;110(6):1361-1369.
18. Ying Z, Mi L, Wang X, Zhang Y, Yang Z, Song Y et al. Prognos- tic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation. Cancer Res 2017;29(6):561-571.
19. Sucak GT, Özkurt ZN, Suyani E, Yaşar DG, Akdemir ÖÜ, Aki Z et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prog- nostic factor with an impact on overall survival. Ann Hematol 2011;90(11):1329-1336.
20. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin›s lymphoma at risk of relapse or progression (AETHERA): a ran- domised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385(9980):1853-1862.
21. Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR et al. Outcomes of patients with relapsed/refractory Hodgkin lympho- ma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. Am J Hematol 2017;92(9):879-884.
22. Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK et al. Role of Consolidative Radiation Therapy After Autolo- gous Hematopoietic Cell Transplantation for the Treatment of Re- lapsed or Refractory Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 2017;99(1):94-102.
23. Dejanovic D, Amtoft A, Loft A. F 18 F-FDG PET/CT in Exten- sive Graft-Versus-Host Disease of the Gastrointestinal Tract Fol- lowing Autologous Stem Cell Transplantation. Diagnostics (Basel). 2018;8(4):72.
24. Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A et al. Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Re- lapse in Lymphoma Patients. Biol Blood Marrow Transplant. 2019 May;25(5):906-911.
25. Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M et al. Only strongly enhanced residual FDG up- take in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. Pediatr Blood Cancer 2019;66(3):e27539.
26. Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Maw- lawi O et al. Chemotherapy Response Assessment by FDG-PET- CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys 2017;97(2):333-338.
27. Kluge R, Chavdarova L, Hoffmann M, Kobe C, Malkowski B, Montravers F et al. Inter-Reader Reliability of Early FDG-PET/ CT Response Assessment Using the DeauvilleScale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin›s Lymphoma. PLoS One 2016;11(3):e0149072.
28. Moskowitz AJ et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. BJH 2009;146(2):158–163
29. Giaccone L et al. Long-term follow-up of allogeneic stem cell trans- plantation in relapsed/refractory Hodgkin lymphoma. Bone Mar- row Transplantation 2017; 52: 1208–1211
30. Chen R et al. Five-year survival and durability results of brentuxi- mab vedotin in patients with relapsed or refractory Hodgkin lym- phoma. Blood 2016;128(12):1562–1566
31. Chen R et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodg- kin lymphoma. Biology of Blood and Marrow Transplantation 2014;20:1864–1868
32. Chen R et al. Phase II Study of the Efficacy and Safety of Pembroli- zumab for Relapsed/Refractory Classic Hodgkin Lymphoma. JCO 2017;35(19):2125-2132
33. Armand P et al. Nivolumab for Relapsed/Refractory Classic Hodg- kin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort .Single- Arm Phase II CheckMate 205 Trial. JCO 2018;36(14):1428-1439
34. Merryman RW et al. Safety and efficacy of allogeneic hematopoi- etic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 2017;129(10):1380-1388
35. Dada R and Usman B. Allogeneic hematopoietic stem cell transplan- tation in r/r Hodgkin lymphoma after treatment with checkpoint in- hibitors: Feasibility and safety. Eur J Haematol 2019;102(2):150-156
36. Broccoli A and Zinzani PL. The role of transplantation in Hodgkin lymphoma. British Journal of Hamatology 2019; 184(1):93-104
37. Herbaux C et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 2018;132(1):9-16
38. Rossi C et al. Efficacy of chemotherapy or chemo-anti-PD-1 com- bination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin Lymphoma: A series from lysa centers. Am J Hematol 2018;93:1042–1049
39. Carlo Stella C et al. Nivolumab restores sensitivity to chemotherapy in chemorefractory classical Hodgkin Lymphoma patients. EHA 2018, poster PS1175
40. Shah GL and Moskowitz CH. Transplant strategies in relapsed/ refractory Hodgkin Lymphoma. Blood 2018; 131(15):1689-1697
41. Cheson BD et al. Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy. Blood 2016;128:2489–2496.
42. Champiat S et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920–1928.
43. Gaudio F, Mazza P, Carella AM, Mele A, et al. Outcomes of Re- duced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multi- center Experience by the Rete Ematologica Pugliese (REP). Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):35-40.
44. Gaudio F, Mazza P, Mele A, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chem- orefractory Hodgkin’s lymphoma patients. Ann Hematol. 2019 Jun;98(6):1449-1455.
45. Robinson SP, Sureda A, Canals C, et al. Lymphoma Working Party of the EBMT. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognos- tic factors predicting outcome. Haematologica. 2009;94:230-238.
46. Sureda A, Robinson S, Canals C, et al. Reduced-intensity condi- tioning compared with conventional allogeneic stem-cell transplan- tation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455- 462.
47. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471-2478.
48. Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221-228.
49. Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and effi- cacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120:560-568.
50. Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in pa- tients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Ital- ian centers. Oncologist. 2015;20:323-328.
51. Tsirigotis P, Danylesko I, Gkirkas K, et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for pa- tients with Hodgkin lymphoma after allogeneic stem cell transplan- tation. Bone Marrow Transplant. 2016;51:1313-1317.
52. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning alloge- neic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93:257-264.
53. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
54. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lym- phoma. J Clin Oncol 2011; 29: 971–978.
55. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantat on is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183.
56. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, An- dersson BS et al. Donor leukocyte infusions (DLIs) in recurrent Hodgkin lymphoma (HL) following allogeneic stem cell transplan- tation: ten-year experience at the M.D. Anderson Cancer Center. Leuk Lymphoma 2012; 53: 1239–1241.
57. Theurich S, Malcher J, Wennhold K et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of- Hodgkin lymphoma after allogeneic stem-cell transplantation in- duces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013;31:e59–e63.
58. Chen YB, McDonough S, Hasserjian R et al. Expression of CD30 in patients with acute graft versus- host disease. Blood 2012;120:691– 696.
59. Bartlett NL, Chen R, Fanale MA et al. Retreatment with brentuxi- mab vedotin in patients with CD30-positive hematologic malig- nancies. J Hematol Oncol 2014;7:24.
60. Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 2017; 54:99–109.
61. Paydas S, Bagir E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PDL1), and EBV- encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol 2015; 94(9):1545–1552.
62. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372(4): 311-319.
63. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodg- kin’s lymphoma after failure of both autologous stem-cell transplan- tation and brentuximab vedotin: a multicentre, multicohort, single- arm phase 2 trial. Lancet Oncol 2016; 17(9):1283-1294.
64. Armand P, Shipp MA, Ribrag V et al. Programmed death-1 block- ade with pembrolizumab in patients with classical Hodgkin lym- phoma after brentuximab vedotin failure. J Clin Oncol 2016 Nov 1;34(31):3733-3739
65. Anastasia A, Carlo-Stella C, Corradini P et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol 2014;166(1):140-142.
66. Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskalt- sis-Mortari et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus- host disease lethality. Blood 2013;122:3062–3073.
67. Schade H, Sen S, Neff CP et al. Programmed death 1 expression on CD41 T cells predicts mortality after allogeneic stem cell trans- plantation. Biol Blood Marrow Transplant 2016;22(12):2172-2179.
68. Sarmen S, Tara S. Acute liver failure from Anti-PD-1 antibody nivolumab in a patient with metastatic lung squamous cell carci- noma. Austin Oncol 2016;1(2):1006.
2. Adams HJ, Kwee TC. Controversies on the prognostic value of in- terim FDG-PET in advanced-stage Hodgkin lymphoma. Eur J Hae- matol 2016; 97(6):491-498.
3. Rigacci L, Puccini B, Zinzani PL et al. Clinical Characteristics of patients with negative interim-PET and positive final PET: data from the prospective PET-oriented HD0801 study by Fondazione Italiana Linfomi (FIL). Hematological Oncology 2017; 35(S2).
4. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Posi- tive Interim Positron Emission Tomography/Computed Tomog- raphy Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Gallamini A, Tarella C, Viviani S, et al. J Clin Oncol 2018; 36(5):454-462.
5. Dann EJ, Bairey O, Bar-Shalom R et al. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on in- terim PET/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol 2017; 178(5):709-718.
6. Borchmann P, Haverkamp H, Lohri A et al. Progression-free sur- vival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol 2017;18(4):454-463.
7. Zinzani PL, Broccoli A, Gioia DM et al. Interim Positron Emis- sion Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. J Clin Oncol 2016;34(12):1376-1385.
8. Rigacci L, Puccini B, Zinzani PL et al. The prognostic value of positron emission tomography performed after two courses (IN- TERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 2015;90(6):499-503.
9. Ciammella P, Filippi AR, Simontacchi G et a. Post-ABVD/pre-ra- diotherapy (18)F-FDG-PET provides additional prognostic infor- mation for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Br J Radiol 2016;89(1061):20150983.
10. Simontacchi G, Filippi AR, Ciammella P et al. Interim PET Af- ter Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Out- comes Following the Continuation of Chemotherapy Plus Radio- therapy. Int J Radiat Oncol Biol Phys 2015;92(5):1077-1083.
11. Keresztes K, Lengyel Z, Devenyi K, Vadasz G, Miltenyi Z, Illes
A. Mediastinal bulky tumour in Hodgkin’s disease and prognostic value of positron emission tomography in the evaluation of post- treatment residual masses. Acta Haematol 2004;112(4):194-199.
12. Sickinger MT, von Tresckow B, Kobe C, Borchmann P, Engert A, Skoetz N. PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis. Crit Rev Oncol Hematol 2016;101:86-92.
13. Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N. Positron emission tomography-adapted therapy for first- line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst Rev 2015; 9;1: CD010533.
14. Adams HJA, de Klerk JMH, Regelink JC, Heggelman BGF, Dubois SV, Kwee TC. Radiation-Induced Giant Cell Granuloma Mimick- ing Relapsed Hodgkin Lymphoma at FDG-PET/CT. Nucl Med Mol Imaging 2017;51(4):371-373.
15. Radhakrishnan RK, Mittal BR, Basher RK, Prakash G, Malhotra P, Kalra N, Das A. Post-therapy lesions in patients with non- Hodgkin’s lymphoma characterized by 18F-FDG PET/CT-guided biopsy using automated robotic biopsy arm. Nucl Med Commun 2018;39(1):74-82.
16. Adams HJ, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol 2016;95(5):695-706.
17. Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al. The impact of pre- and post-transplantation positron emis- sion tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplanta- tion. Cancer 2007;110(6):1361-1369.
18. Ying Z, Mi L, Wang X, Zhang Y, Yang Z, Song Y et al. Prognos- tic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation. Cancer Res 2017;29(6):561-571.
19. Sucak GT, Özkurt ZN, Suyani E, Yaşar DG, Akdemir ÖÜ, Aki Z et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prog- nostic factor with an impact on overall survival. Ann Hematol 2011;90(11):1329-1336.
20. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin›s lymphoma at risk of relapse or progression (AETHERA): a ran- domised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385(9980):1853-1862.
21. Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR et al. Outcomes of patients with relapsed/refractory Hodgkin lympho- ma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis. Am J Hematol 2017;92(9):879-884.
22. Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK et al. Role of Consolidative Radiation Therapy After Autolo- gous Hematopoietic Cell Transplantation for the Treatment of Re- lapsed or Refractory Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 2017;99(1):94-102.
23. Dejanovic D, Amtoft A, Loft A. F 18 F-FDG PET/CT in Exten- sive Graft-Versus-Host Disease of the Gastrointestinal Tract Fol- lowing Autologous Stem Cell Transplantation. Diagnostics (Basel). 2018;8(4):72.
24. Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A et al. Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Re- lapse in Lymphoma Patients. Biol Blood Marrow Transplant. 2019 May;25(5):906-911.
25. Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M et al. Only strongly enhanced residual FDG up- take in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. Pediatr Blood Cancer 2019;66(3):e27539.
26. Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Maw- lawi O et al. Chemotherapy Response Assessment by FDG-PET- CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys 2017;97(2):333-338.
27. Kluge R, Chavdarova L, Hoffmann M, Kobe C, Malkowski B, Montravers F et al. Inter-Reader Reliability of Early FDG-PET/ CT Response Assessment Using the DeauvilleScale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin›s Lymphoma. PLoS One 2016;11(3):e0149072.
28. Moskowitz AJ et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. BJH 2009;146(2):158–163
29. Giaccone L et al. Long-term follow-up of allogeneic stem cell trans- plantation in relapsed/refractory Hodgkin lymphoma. Bone Mar- row Transplantation 2017; 52: 1208–1211
30. Chen R et al. Five-year survival and durability results of brentuxi- mab vedotin in patients with relapsed or refractory Hodgkin lym- phoma. Blood 2016;128(12):1562–1566
31. Chen R et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodg- kin lymphoma. Biology of Blood and Marrow Transplantation 2014;20:1864–1868
32. Chen R et al. Phase II Study of the Efficacy and Safety of Pembroli- zumab for Relapsed/Refractory Classic Hodgkin Lymphoma. JCO 2017;35(19):2125-2132
33. Armand P et al. Nivolumab for Relapsed/Refractory Classic Hodg- kin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort .Single- Arm Phase II CheckMate 205 Trial. JCO 2018;36(14):1428-1439
34. Merryman RW et al. Safety and efficacy of allogeneic hematopoi- etic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood 2017;129(10):1380-1388
35. Dada R and Usman B. Allogeneic hematopoietic stem cell transplan- tation in r/r Hodgkin lymphoma after treatment with checkpoint in- hibitors: Feasibility and safety. Eur J Haematol 2019;102(2):150-156
36. Broccoli A and Zinzani PL. The role of transplantation in Hodgkin lymphoma. British Journal of Hamatology 2019; 184(1):93-104
37. Herbaux C et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 2018;132(1):9-16
38. Rossi C et al. Efficacy of chemotherapy or chemo-anti-PD-1 com- bination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin Lymphoma: A series from lysa centers. Am J Hematol 2018;93:1042–1049
39. Carlo Stella C et al. Nivolumab restores sensitivity to chemotherapy in chemorefractory classical Hodgkin Lymphoma patients. EHA 2018, poster PS1175
40. Shah GL and Moskowitz CH. Transplant strategies in relapsed/ refractory Hodgkin Lymphoma. Blood 2018; 131(15):1689-1697
41. Cheson BD et al. Refinement of the Lugano classification response criteria for lymphoma in the era of immunomodulatory therapy. Blood 2016;128:2489–2496.
42. Champiat S et al. Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920–1928.
43. Gaudio F, Mazza P, Carella AM, Mele A, et al. Outcomes of Re- duced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multi- center Experience by the Rete Ematologica Pugliese (REP). Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):35-40.
44. Gaudio F, Mazza P, Mele A, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chem- orefractory Hodgkin’s lymphoma patients. Ann Hematol. 2019 Jun;98(6):1449-1455.
45. Robinson SP, Sureda A, Canals C, et al. Lymphoma Working Party of the EBMT. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognos- tic factors predicting outcome. Haematologica. 2009;94:230-238.
46. Sureda A, Robinson S, Canals C, et al. Reduced-intensity condi- tioning compared with conventional allogeneic stem-cell transplan- tation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455- 462.
47. Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471-2478.
48. Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221-228.
49. Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and effi- cacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120:560-568.
50. Carlo-Stella C, Ricci F, Dalto S, et al. Brentuximab vedotin in pa- tients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Ital- ian centers. Oncologist. 2015;20:323-328.
51. Tsirigotis P, Danylesko I, Gkirkas K, et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for pa- tients with Hodgkin lymphoma after allogeneic stem cell transplan- tation. Bone Marrow Transplant. 2016;51:1313-1317.
52. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning alloge- neic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93:257-264.
53. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
54. Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lym- phoma. J Clin Oncol 2011; 29: 971–978.
55. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantat on is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172–183.
56. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, An- dersson BS et al. Donor leukocyte infusions (DLIs) in recurrent Hodgkin lymphoma (HL) following allogeneic stem cell transplan- tation: ten-year experience at the M.D. Anderson Cancer Center. Leuk Lymphoma 2012; 53: 1239–1241.
57. Theurich S, Malcher J, Wennhold K et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of- Hodgkin lymphoma after allogeneic stem-cell transplantation in- duces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013;31:e59–e63.
58. Chen YB, McDonough S, Hasserjian R et al. Expression of CD30 in patients with acute graft versus- host disease. Blood 2012;120:691– 696.
59. Bartlett NL, Chen R, Fanale MA et al. Retreatment with brentuxi- mab vedotin in patients with CD30-positive hematologic malig- nancies. J Hematol Oncol 2014;7:24.
60. Ok CY, Young KH. Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev 2017; 54:99–109.
61. Paydas S, Bagir E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PDL1), and EBV- encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol 2015; 94(9):1545–1552.
62. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372(4): 311-319.
63. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodg- kin’s lymphoma after failure of both autologous stem-cell transplan- tation and brentuximab vedotin: a multicentre, multicohort, single- arm phase 2 trial. Lancet Oncol 2016; 17(9):1283-1294.
64. Armand P, Shipp MA, Ribrag V et al. Programmed death-1 block- ade with pembrolizumab in patients with classical Hodgkin lym- phoma after brentuximab vedotin failure. J Clin Oncol 2016 Nov 1;34(31):3733-3739
65. Anastasia A, Carlo-Stella C, Corradini P et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol 2014;166(1):140-142.
66. Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskalt- sis-Mortari et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus- host disease lethality. Blood 2013;122:3062–3073.
67. Schade H, Sen S, Neff CP et al. Programmed death 1 expression on CD41 T cells predicts mortality after allogeneic stem cell trans- plantation. Biol Blood Marrow Transplant 2016;22(12):2172-2179.
68. Sarmen S, Tara S. Acute liver failure from Anti-PD-1 antibody nivolumab in a patient with metastatic lung squamous cell carci- noma. Austin Oncol 2016;1(2):1006.
Downloads
Published
25-05-2020
Issue
Section
How I Treat
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
1.
Di Renzo N, Gaudio F, Carlo Stella C, Oppi S, Pelosini M, Sorasio R, et al. Relapsing/refractory HL after autotransplantation: which treatment?. Acta Biomed [Internet]. 2020 May 25 [cited 2024 Jul. 27];91(S-5):30-4. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/9912
